Media

Orexo launches deprexis® and vorvida® in the US and provides updated financial guidance

Strongbridge Biopharma plc Announces Last Patient Completes Last Study Visit in the Randomized Withdrawal Phase of the LOGICS Trial Evaluating RECORLEV® (levoketoconazole) for Endogenous Cushing’s Syndrome

Oncopeptides announces leadership changes: Jakob Lindberg assumes a new role as CSO, and Marty J Duvall is appointed CEO

Positive results from human PK study assessing Orexo’s intranasal nalmefene formulations for opioid overdose reversal

Oncopeptides submits a New Drug Application to the FDA for accelerated approval of melflufen in triple-class refractory multiple myeloma patients

Nordic Nanovector to amend PARADIGME trial protocol to expand eligible patient population

Oncopeptides strengthens the pre-clinical development and takes over Kancera´s Solna-based laboratory for drug development as of July 1

Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directors

Nordic Nanovector’s Betalutin® Receives Fast-Track Designation from US FDA for Marginal Zone Lymphoma